Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, lenalidomide (Revlimid®) cannot be endorsed for use within NHS Wales as combination therapy with bortezomib and dexamethasone, or melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. |
||
|
||
Medicine details |
||
| Medicine name | lenalidomide (Revlimid®) | |
| Formulation | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsule | |
| Reference number | 4171 | |
| Indication | Combination therapy with bortezomib and dexamethasone, or melphalan and prednisone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant |
|
| Company | Celgene Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 16/09/2019 | |